Previous 10 | Next 10 |
I-Mab Receives Top Rankings in Five Categories by Institutional Investor PR Newswire GAITHERSBURG, Md. and SHANGHAI , June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed t...
Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 PR Newswire SHANGHAI and GAITHERSBURG, Md. , June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to...
Chinese biotech I-Mab (NASDAQ:IMAB -0.3%) completed patient enrollment in a phase 3 clinical trial testing its growth hormone therapy, eftansomatropin alfa, also known as GX-H9/TJ101, in China. Eftansomatropin alfa was discovered by Korean firm Genexine and is being co-developed by Genex...
Shanghai Fosun Pharma will pay $158 million to acquire a 60% stake in a Singapore oncology medical center chain, Oncocare Medical Pte. OnCusp Therapeutics, a New York-Shanghai biopharma, acquired global rights (ex-China) to a pre-clinical CDH6 antibody drug conjugate from Multitude Th...
Switzerland-based Ferring Pharmaceuticals said it entered a strategic collaboration with China's I-Mab (NASDAQ:IMAB) to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions. Financial details were not undisclosed, as per the June 9 press release. ...
Commenting on a recent data readout announced by Chinese biotech I-Mab (NASDAQ:IMAB) for its CD73 antibody uliledlimab, H.C. Wainwright issued mixed views on the lung cancer candidate on Tuesday. The initial data from the ongoing trial on Thursday is scheduled for a presentation at this week&...
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency PR Newswire SHANGHAI and GAITHERSBURG, Md. , May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (...
Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (ARCT) +19%. Red Rob...
The shares of I-Mab (NASDAQ:IMAB) are trading sharply lower in the morning hours Friday after the Chinese biotech announced early Phase 2 data for its CD73 antibody uliledlimab in combination with Coherus’ (CHRS) anti-PD1 therapy, toripalimab (TUOYI) in lung cancer. The updated data li...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...